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Oxidative stress activates the NF-kB/Rel transcription factors which are involved in the activation of numerous immunoreg-
ulatory genes and the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). In the present study, we
examined the effects of established and novel compounds including antioxidants, ribonucleotide reductase inhibitors, and
iron chelators on NF-kB activation and HIV LTR-mediated gene expression induced by TNF-a. N-Acetylcysteine (NAC),
pyrrolidinedithiocarbamate (PDTC), and Trimidox (TD) at various concentrations inhibited TNF-a-induced NF-kB binding in
Jurkat cells. Pretreatment of cells with these compounds prior to stimulation prevented IkBa degradation. Phosphorylation
of IkBa, a prerequisite for its signal-induced degradation, was abrogated in these cells, indicating that oxidative stress is
an essential step in the NF-kB activation pathway. On the other hand, iron chelators desferrioxamine, pyridoxal isonicotinoyl
hydrazone (PIH), and salicylaldehyde isonicotinoyl hydrazone (SIH) showed no inhibition of TNF-a-induced NF-kB DNA-
binding activity. Synergistic induction of HIV-1 LTR-mediated gene expression by TNF-a and the HIV-1 transactivator Tat
in Jurkat cells was significantly suppressed in the presence of NAC and TD, but not PDTC. The inhibition of NAC and TD
on LTR-directed gene expression was diminished when NF-kB-binding sites in the LTR were deleted, indicating that these
compounds affected the NF-kB component of the synergism. Iron chelators PIH and SIH also showed some inhibitory
effect on LTR-mediated gene activation, presumably through an NF-kB-independent mechanism. These experiments demon-
strate that TD, at concentration 50 times lower than the effective concentration of NAC, potently inhibits NF-kB activity and
suppresses HIV LTR expression. q 1997 Academic Press
INTRODUCTION plasm of the cell, sequestered by binding to a family of
inhibitory molecules, the IkBs. The IkB proteins identified
Numerous studies have demonstrated that reagents
so far include IkBa (Haskill et al., 1991), IkBb (Thompson
inducing a significant level of oxidative stress lead to
et al., 1995), IkBg (Gerondakis et al., 1993; Inoue et al.,
the activation of the transcription factor NF-kB and this
1992), and Bcl-3 (Hatada et al., 1992; Naumann et al.,
activation can be inhibited by the addition of various
1993), as well as the precursor proteins p105 (Liou et
antioxidants (Schreck et al., 1991, 1992b; Sen et al., 1996;
al., 1992) and p100 (Mercurio et al., 1993); all IkBs contain
Meyer et al., 1993; Staal et al., 1995). The NF-kB/Rel
between five and seven repeats of a 33-amino-acid se-
family of transcription factors plays a pivotal role in the
quence termed the ankyrin motif. The ankyrin repeat mo-
regulation of inflammatory and immunoregulatory genes,
tif confers the inhibitory function of IkB proteins by bind-
including cytokines, cell surface receptors, and acute-
ing to and masking the nuclear localization sequence onphase proteins, as well as viral genes including the hu-
NF-kB, thus retaining NF-kB/Rel in the cytoplasm.man immunodeficiency virus type 1 (HIV-1) long terminal
Activation of NF-kB DNA-binding activity is initiatedrepeat (LTR) (for review see Baeuerle et al., 1994; Rouls-
by an immense array of inducing agents including viruston et al., 1995; Verma et al., 1995).
infection, cytokines such as TNF-a and IL-1, lipopolysac-NF-kB/Rel is a family of dimer-forming DNA-binding
charides, and agents inducing oxidative stress and thetranscription factors present in the cytoplasm in an inac-
production of reactive oxygen intermediates (ROI). NF-tive form. Members of the NF-kB/Rel family share a re-
kB activation involves rapid degradation of IkBa and/orgion of homology that spans the N-terminal 300 amino
IkBb (Baeuerle et al., 1988), thereby releasing NF-kBacids known as the NF-kB/Rel/dorsal region which is
subunits, which can then translocate into the nucleusresponsible for DNA binding, dimerization, and nuclear
and transactivate target genes (Beg et al., 1992, 1993a),translocation of NF-kB. In unstimulated cells, inactive
including its own inhibitor IkBa (Sun et al., 1993). Thehetero- or homodimers of NF-kB are found in the cyto-
most extensively studied IkB subunit—IkBa—becomes
rapidly hyperphosphorylated upon inducer-mediated
1 To whom correspondence and reprint requests should be ad-
stimulation at serines 32 and 36 in the signal responsedressed at the Lady Davis Institute for Medical Research, 3755 Cote
domain of the protein (Ghosh et al., 1990; Beg et al.,Ste. Catherine, Montreal, Quebec, Canada H3T1E2. Fax: (514) 340-
7576. E-mail: MIJH@musica.mcgill.ca. 1993b; Brown et al., 1993; Sun et al., 1996; Traenckner
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et al., 1995). Phosphorylation represents a signal for the (DD), and Trimidox (TD); and (3) iron chelators—desferri-
oxamine (desferal), pyridoxal isonicotinoyl hydrazonesubsequent ubiquitination of IkBa at lysines 21 and 22
(Chen et al., 1995; Scherer et al., 1995; Alkalay et al., (PIH), and salicylaldehyde isonicotinoyl hydrazone (SIH).
Although structurally unrelated, all of these compounds1995b). Neither phosphorylation nor ubiquitination im-
pairs the ability of IkBa to associate with NF-kB but alter the intracellular redox state via different mecha-
nisms and actions. The present study was undertakenrepresents a signal for degradation by the 26S protea-
some complex (DiDonato et al., 1995; Traenckner et al., to evaluate the efficacy of these antioxidant compounds
in the selective inhibition of Tat–TNF-a synergistic acti-1994; Alkalay et al., 1995a). The nature of the kinase
responsible for inducer-mediated phosphorylation of vation of HIV-1 LTR-mediated gene activity. We report
here that established and novel antioxidant compoundsIkBa has yet to be defined, although a recent study dem-
onstrated that a large 700-kDa multisubunit complex, it- selectively inhibit signal-induced phosphorylation of
IkBa, NF-kB DNA-binding activity, and gene activation,self dependent on ubiquitination for activation, may be
involved (Chen et al., 1996). IkBa is also constitutively supporting the idea that oxidative stress contributes to
the NF-kB induction mechanism. Our results indicate thatphosphorylated in the C-terminal PEST domain of the
protein at multiple casein kinase II sites (Lin et al., 1996; compounds capable of interfering with the activation of
the NF-kB/IkB pathway may be a useful therapeutic strat-Barroga et al., 1995; Schwarz et al., 1996). Although NF-
kB activity can be induced by a large number of stimuli, egy to block the induction of inflammatory cytokines or
viral regulatory genes.most if not all can be inhibited by the addition of antioxi-
dant reagents (Baeuerle et al., 1994; Schreck et al., 1991).
In addition, administration of hydrogen peroxide and METHODS AND MATERIALS
overexpression of glutathione peroxidase can lead to
Cell cultureinduction or inhibition, respectively, of NF-kB activity
(Schreck et al., 1991; Kretz-Remy et al., 1996; Meyer et Human lymphoma Jurkat T-cells were maintained in
al., 1993). Therefore, an intermediate step in the NF-kB RPMI 1640 medium (GIBCO Life Technologies, Inc.,
activation pathway appears to be the generation of oxida- Grand Island, NY) supplemented with 10% fetal bovine
tive stress and ROI (Suzuki et al., 1994; Sen et al., 1996; serum, 2 mM L-glutamine, and 10 mg of gentamicin
Beauparlant et al., 1996a). (Schering Canada, Pointe Claire, Quebec). Tat-express-
The NF-kB/Rel pathway also plays a crucial role in the ing Jurkat cells (Jurkat-Tat) were cultured similarly to Jur-
intracellular efficiency of gene expression and replication kat cells and with the addition of 400 mg/ml G418 (GIBCO)
of HIV-1. The transcriptional activation of the HIV LTR as the selection drug. Murine NIH 3T3 fibroblasts were
largely depends on an enhancer element which consists maintained in Dulbecco’s modified minimal medium
of two tandem NF-kB-binding sites. Previous studies (DMEM) supplemented with 10% calf serum, 2 mM L-
showed that in addition to its ability to bind to the TAR glutamine, and 10 mg of gentamicin.
site on LTR, HIV-1 transactivator protein Tat amplified
the activity of TNF-a with regard to TNF-a-induced activa- Plasmids and reagents
tion of NF-kB due to an alteration of the cellular redox
HIV LTR CAT plasmids ptzIIICAT, 0109/079, IIID23,state toward a more prooxidative condition (Westendorp
and IIIDA were a kind gift from Dr. Eric Cohen. Theet al., 1995). Also, synergistic activation of HIV LTR-driven
Tat-expressing plasmid pSVexTat, provided by Dr. N.gene expression by Tat protein and TNF-a can be
Sonenberg, was previously described (Roy et al., 1990;blocked by transdominant mutants of IkBa, which are
Delling et al., 1991). The CAT reporter constructs pHI-extremely stable, even in the presence of inducer (Beau-
Venh-CAT contain a single copy of the HIV-1 enhancerparlant et al., 1996b). Given that TNF-a levels are ele-
(0105 to 080) linked to the basal SV40 promotervated in the serum of patients with AIDS (Lahdevirta et
(Leblanc et al., 1990), while the 5*kB(3) CAT is a modifi-al., 1988), it seems that inhibition of the synergistic activa-
cation of pHIVenh-CAT in which three tandem copiestion of the LTR has great pathophysiological relevance.
of HIV-1 enhancer are linked to the basal SV40 pro-The association between ROI induction of NF-kB and the
moter. NAC (Boeringer Mannheim GmbH) and PDTCcontrol of HIV-1 transcription by NF-kB has led to the
(Sigma) were dissolved in phosphate-buffered salinesuggestion that antioxidant drugs may have therapeutic
(PBS) and the pH was adjusted to 7.5 with NaOH. Ami-use in the treatment of HIV-associated disease.
dox, Didox, Trimidox (Molecules for Health, Inc.), andIn the present study, we employed several novel or
desferal were dissolved in water. PIH and SIH werewell-established antioxidant compounds to examine their
prepared by dissolving in PBS.effects on NF-kB activation or HIV LTR-mediated gene
expression. These compounds can be categorized into Electromobility shift assay (EMSA)
three general groups: (1) established antioxidants— N-
acetylcysteine (NAC) and pyrrolidinedithiocarbamate Nuclear extracts (Osborn et al., 1989) were prepared
from untreated cells or cells treated 3 hr with TNF-a (10(PDTC); (2) novel ribonucleotide reductase inhibitors with
free radical scavenging activity—Amidox (AD), Didox ng/ml). Briefly, cells were washed in Buffer A [10 mM
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HEPES, pH 7.9; 1.5 mM MgCl2 ; 10 mM KCl; 0.5 mM transferred to nitrocellulose membrane. IkBa and phos-
phorylated IkBa were visualized using the monoclonaldithiothreitol (DTT); and 0.5 mM phenylmethylsulfonyl flu-
oride (PMSF)] and were resuspended in Buffer A con- IkBa antibody MAD 10B.
taining 0.1% NP-40. Cells were then chilled on ice for 10
min before being centrifuged at 10,000 g. Pellets were Analysis of HIV-1 LTR- and NF-kB-dependent gene
expressionthen resuspended in Buffer B (20 mM HEPES, pH 7.9;
25% glycerol; 0.42 M NaCl; 1.5 mM MgCl2 ; 0.2 mM EDTA;
Jurkat or Jurkat-Tat cells were transiently transfected0.5 mM DTT; 0.5 mM PMSF; 5 mg/ml leupeptin; 5 mg/ml
by the DEAE-dextran method (Lacoste et al., 1990). Thepepstatin; 0.5 mM spermidine; 0.15 mM spermine; and
precipitated DNAs (10 mg), representing the different HIV-5 mg/ml aprotinin). Samples were incubated on ice for
LTR CAT or NF-kB-dependent reporter plasmids and the15 min before being centrifuged at 10,000 g. Nuclear
pSVexTat plasmid were resuspended in TS solution (8extract supernatants were diluted with Buffer C (20 mM
mg/ml NaCl, 0.38 mg/ml KCl, 0.1 mg/ml Na2HPO4r7H2O,HEPES, pH 7.9; 20% glycerol; 0.2 mM EDTA; 50 mM KCl;
3.0 ml Tris, 0.1 mg/ml MgCl2 , and 0.1 mg/ml CaCl2 , pH0.5 mM DTT; and 0.5 mM PMSF). Nuclear extracts were
7.4). After resuspension, 0.5 mg of DEAE-dextran (Phar-subjected to EMSA by using a 32P-labeled probe corre-
macia) was added. For each transfection, 1 1 107 cellssponding to the PRD II region of the IFN-b promoter (5*-
in exponential phase were washed once in TS, resus-GGGAAATTCCGGGAAATTCC-3*) or the HIV-1 enhancer
pended with the DNA solution, and incubated at roomsequence as described (5*-AGGGACTTTCCGCTGGGA-
temperature for 20 min. Cells were then incubated atCTTTCC-3*) (Garoufalis et al., 1994). The resulting pro-
377C for 30 min in RPMI (10 ml) containing 10% fetaltein–DNA complexes were resolved by 5% Tris–glycine
bovine serum and 0.1 mM chloroquine (Sigma Chemicalgel and exposed to X-ray film. To demonstrate the speci-
Co.), after which they were centrifuged and resuspendedficity of protein–DNA complex formation, 125-molar-fold
in fresh DMEM and fetal bovine serum. At 24 hr afterexcess of unlabeled oligonucleotide was added to the
transfection, cells were induced with 5 ng/ml TNF-anuclear extract before adding the labeled probe. For su-
(Boeringer Mannheim). At 16–20 hr after TNF-a induc-pershift assay, rabbit polyclonal antibody (1 ml) directed
tion, cells were harvested and lysed by freeze–thaw.against human c-Rel, p105/p50, p65, or p100/p52 (Rouls-
Extracts (20–100 mg) were assayed for CAT activity forton et al., 1993) were incubated with nuclear extracts for
1 to 4 hr, depending on the experiment. The percentage20 min at room temperature prior to the incubation with
of acetylation was determined by ascending thin-layerprobe. The resulting complexes were analyzed in EMSA
chromatography as previously described and quantifiedand subsequently quantified by laser densitometry.
using the Bio-Rad Gelscan PhosphoImager and the Mo-
lecular Analyst software program.Immunoblot analysis of IkBa turnover
Jurkat cells were cultured in RPMI 1640 media supple- RESULTS
mented with 10% fetal bovine serum. After 1 hr of pre-
Structure and function of compounds used in thistreatment with different compounds (as specified in the
studyindividual experiments), cells were treated with 5 ng/ml
TNF-a (GIBCO BRL) and 50 mg/ml cycloheximide. At 2 hr
Structural schematics of the compounds utilized in this
after induction, cells were washed with PBS and lysed
study are shown in Fig. 1. NAC functions as an antioxi-
in Western lysis buffer (10 mM Tris–HCl, pH 8.0; 60 mM
dant because it can replenish intracellular glutathione
KCl; 1 mM EDTA; 1 mM DTT; 0.5% NP-40; 0.5 mM PMSF;
(GSH), which is a major component of the cellular de-
0.01 mg/ml leupeptin; 0.01 mg/ml pepstatin; and 0.01 mg/
fense mechanism against oxidative stress (De Vries et
ml aprotinin). Equivalent amounts of protein (20 mg) were
al., 1993; Staal et al., 1995). In addition, NAC also protects
electrophoresed on a 10% SDS–polyacrylamide gel. Pro-
DNA and nuclear enzymes from oxidative stress-induced
tein was transferred to a nitrocellulose membrane and
damage and prevents the formation of carcinogen–DNA
IkBa, IkBb, and actin were detected using IkBa mono-
adducts. PDTC is a derivative of the dithiocarbamate fam-
clonal antibody MAD 10B (a kind gift from Dr. R. Hay),
ily of compounds, exploited for decades for the treatment
IkBb (C-20; Santa Cruz, Inc.), or mouse anti-actin mono-
of metal poisonings (Sunderman et al., 1967). PDTC may
clonal antibody (ICN), respectively. Bands corresponding
possess at least two chemical activities inside the cell:
to IkBa were quantified by laser densitometry.
heavy metal chelation and antioxidant activity. The latter
property is primarily due to its dithiocarboxy group whichDetection of IkBa phosphorylation
functions like GSH and neutralizes ROI (Schreck et al.,
1992b). Desferal has been used as a treatment of ironCell extracts were prepared as for immunoblot analy-
sis except cells were pretreated for 30 min with 100 mM overload for over 2 decades (Barry et al., 1974; Mondell
et al., 1982). Together with PIH and SIH, which belong tocalpain inhibitor I prior to stimulation by TNF-a. Equiva-
lent amounts of protein (30 mg) were resolved using a 5– the acyl hydrazone family of iron chelators, these highly
effective iron-chelating compounds significantly reduce13% gradient or 15% SDS –polyacrylamide gel and were
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FIG. 1. Structures of compounds used in this study. (A) Structure of antioxidants NAC and PDTC. (B) Structure of ribonucleotide reductase
inhibitors Amidox, Didox, and Trimidox. (C) Structure of iron chelators desferal, PIH, and SIH.
hydroxyl radical generation and oxyradical-induced injur- EMSA. Incubation of control cells with the compounds
ies (Baker et al., 1992; Schulman et al., 1995). Uncom- alone either had no effect on NF-kB-binding activity in
plexed iron with superoxide and peroxide can yield highly the case of NAC (Fig. 2A, lane 2) or slightly stimulated
reactive radicals by the Fenton reaction, and by chelating NF-kB-binding activity in the cases of PDTC and TD (Fig.
free iron, these compounds regulate the intracellular re- 2A, lanes 3 and 4). TNF-a increased NF-kB-binding activ-
dox status. Amidox, Didox, and Trimidox are a series of ity more than 30-fold relative to the uninduced control
polyhydroxyphenyl derivatives designed to inhibit ribonu- (Fig. 2A, lanes 1 and 5) and this binding activity was
cleotide reductase (Szekeres et al., 1994a,b; Elford et al., inhibited to various degrees by pretreatment of cells with
1989) by free radical scavenging in addition to their iron- antioxidants prior to TNF-a stimulation. Pretreatment of
chelating and antioxidant abilities (Szekeres et al., 1995). cells with 50 mM NAC led to a 10-fold reduction in bind-
ing activity while 0.1 mM PDTC and 1.0 mM TD de-
Inhibition of NF-kB activity by antioxidants creased DNA binding activity by 4-fold and 1.5-fold, re-
spectively (Fig. 2A, lanes 6–8). In a separate experiment,Since previous studies have established that NF-kB
pretreatment of cells with a higher concentration of TDDNA-binding activity is inhibited by the addition of antiox-
(5 mM) led to more prominent inhibitory effect on NF-kBidants (Schreck et al., 1991, 1992b), we initially sought
DNA-binding activity (Fig. 2A, lanes 15 and 16). Amongto examine the inhibitory effects of several novel com-
the three ribonucleotide reductase inhibitors, TD demon-pounds (AD, DD, TD, PIH, and SIH) relative to the estab-
strated the strongest inhibitory activity with respect tolished antioxidant or iron-chelating compounds NAC,
NF-kB activity (Fig. 2A, lanes 11 to 16). In contrast, ironPDTC, and desferal. NF-kB DNA-binding activity was ex-
chelators desferal, PIH, and SIH exhibited no obviousamined in Jurkat T-lymphocytes following induction by
inhibitory effect on NF-kB activity induced by TNF-a (Fig.TNF-a; Jurkat T-cells were incubated in the absence (Fig.
2A, lanes 17–25). Similar analyses were performed using2A, lanes 1, 5, 9, and 10) or the presence (Fig. 2A, lanes
Jurkat T cells which stably expressed HIV Tat protein2–4, 6–8, and 11–25) of compounds for 1 hr. After induc-
(Jurkat-Tat) (Fig. 2B). A detectable increase in the basaltion with TNF-a for 2 hr, nuclear extracts were prepared
and analyzed for NF-kB-specific binding activity by level of NF-kB-binding activity was observed in Jurkat-
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FIG. 2. The effect of antioxidants and iron chelators on the activation of NF-kB by TNF-a. Jurkat cells and Jurkat-Tat cells were stimulated with
10 ng/ml TNF-a for 3 hr in the absence or presence of the indicated compounds. Nuclear extracts were prepared and 5 mg of protein was analyzed
for NF-kB-specific DNA binding in EMSA using a 32P-labeled DNA probe as described under Methods and Materials. The top halves of the
autoradiographs are presented. Specific NF-kB complexes are shown; faster migrating complexes indicated with asterisk are not specific. (A) The
effect of antioxidants on Jurkat cells. Cells were preincubated for 1 hr with 50 mM NAC (lanes 2 and 6), 0.1 mM PDTC (lanes 3 and 7), 1 or 5 mM
AD (lanes 11 and 12, respectively), 1 or 5 mM DD (lanes 13 and 14, respectively), or 1 mM (lanes 4, 8, and 15) or 5 mM (lanes 16) TD or for 17 hr
with 10 mM to 1 mM desferal (lanes 17 to 19), 10 mM to 1 mM PIH (lanes 20 to 22), or 10 mM to 1 mM SIH (lanes 23 to 25) before TNF-a induction.
(B) Similar experiment using Jurkat-Tat cells. Cells were preincubated for 1 hr with 50 mM NAC (lanes 4 and 8), 0.1 mM PDTC (lanes 5 and 9), and
1 mM (lanes 6 and 10) TD before TNF-a induction.
Tat cells (Fig. 2B, lane 3) compared to Jurkat cells (Fig. NF-kB complex (Fig. 3, lane 1) was competed by the
addition of a 125-molar excess of unlabeled NF-kB2B, lane 1), in agreement with the recent observation
probe, indicating the specificity of the complex (Fig. 3,made by Demarchi et al. (1996). As in Jurkat cells, induc-
lane 2). Addition of anti-RelA resulted in a prominenttion of Jurkat-Tat cells with TNF-a led to a dramatic in-
crease (20-fold) in NF-kB binding which was inhibited by
pretreatment with NAC, PDTC, and TD (10-fold, 3-fold,
and 1.5-fold inhibition, respectively) (Fig. 2B, lanes 8 to
10). These initial experiments demonstrated that NAC,
PDTC, and TD differentially inhibited NF-kB activity in-
duced by TNF-a in Jurkat cells, whereas desferal, PIH,
and SIH had no inhibitory effect.
Analysis of subunit composition in NF-kB complex
To further characterize the nature of the NF-kB – DNA
complexes formed after TNF-a treatment, antibodies di-
rected against individual NF-kB subunits [NF-kB1(p50/
p105), NF-kB2(p52/p100), RelA(p65), and c-Rel] were
used in a shifted-shift assay to identify the various sub-
FIG. 3. Characterization of the TNF-a-induced NF-kB–DNA complex.units present in the complex. Antibodies were added to
Nuclear extracts from control or 2-hr TNF-a-treated Jurkat (lanes 1 to
the reaction mix prior to the addition of the radioactive 6) or Jurkat-Tat (lanes 7 to 11) cells were prepared and incubated with
NF-kB probe and the resulting complexes were re- specific antibodies against the NF-kB subunits p50 (lanes 3 and 8),
p52 (lanes 4 and 9), p65 (lanes 5 and 10), and c-Rel (lanes 6 and 11).solved by nondenaturing gel (Fig. 3). The TNF-induced
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shifting of the NF-kB complex, indicating that Rel-A (p65)
is a major component of the complex (Fig. 3, lanes 5
and 10). Anti-NF-kB1 and anti-c-Rel antibodies also re-
sulted in the upshift of a portion of the complex, al-
though to a lesser extent than with anti-RelA (Fig. 3,
lanes 3, 6, 8, and 11). The two shifted complexes ob-
served with anti-NF-kB1 antibody likely represent p50
homodimers and the p50 – p65 heterodimers of NF-kB
(Fig. 3, lanes 3 and 8). A longer exposure of the gel
(data not shown) revealed a small amount of a shifted
complex corresponding to NF-kB2(p52), indicating the
presence of this NF-kB subunit in the complex as well.
The major difference between Jurkat and Jurkat-Tat
complexes was the greater relative abundance of RelA
and c-Rel in the Jurkat-Tat cells (Fig. 3, lanes 7 to 11).
Antioxidants prevent IkBa degradation upon TNF-a
induction
Since signal-induced proteolytic degradation of IkBa
precedes the appearance of NF-kB DNA-binding activity,
we next examined the correlation between the inhibition
of NF-kB activity and the loss of detectable IkBa by anti-
oxidants (Fig. 4). Jurkat T cells or NIH 3T3 fibroblasts
were pretreated with different antioxidants for 1 hr before
induction with TNF-a and cycloheximide. At 2 hr after
induction, whole-cell extracts were prepared and ana-
lyzed for IkBa, IkBb, and actin by immunoblotting. IkBa
was degraded upon TNF-a induction (Fig. 4A, lane 3);
degradation was completely blocked by pretreating cells
with 30 mM NAC (Fig. 4A, lane 4), 5 mM Trimidox (Fig.
4A, lane 6), and 0.1 mM PDTC (Fig. 4A, lane 7). Inhibition
of IkBa degradation was not observed with desferal at
concentrations ranging from 50 mM to 10 mM (Fig. 4A,
lanes 9 to 14). In a separate experiment, the inhibitory
effects on IkBa degradation of the three ribonucleotide
reductase inhibitors—Amidox, Didox, and Trimidox—
were compared directly (Fig. 4B, lanes 5 to 10, top). Trimi-
dox was clearly the best inhibitor of IkBa degradation FIG. 4. Immunoblot analysis of IkB degradation in the presence or
absence of antioxidants. Jurkat or NIH 3T3 cells were cultured in pres-(Fig. 4B, lanes 9 and 10). In this experiment, the level of
ence of cycloheximide and were either untreated or pretreated 1 hrIkBb remained unchanged after TNF-a addition (Fig. 4B,
with antioxidants prior to TNF-a treatment for 2 hr. Protein (20 mg)lanes 1 to 10, middle) as did actin levels (Fig. 4B, lanes 1
extracts were resolved by SDS–PAGE, transferred to nitrocellulose,
to 10, bottom). Using NIH 3T3 cells, which show complete and visualized with antibodies specific to different proteins. (A) Immu-
intracellular disappearance of IkBa upon TNF-a stimula- noblot of IkBa degradation in Jurkat cells. Cells were pretreated 1 hr
with 50 mM NAC (lane 4), 1 (lane 5) or 5 mM (lane 6) TD, 0.1 (lane 7)tion, the effects of iron chelators desferal, PIH, and SIH
or 0.5 mM (lane 8) PDTC, and 50 mM to 10 mM (lanes 9 to 14) desferal.on IkBa degradation were examined. These compounds
(B) Cells were pretreated 1 hr with 50 mM NAC (lane 3), 0.1 mM PDTCwere unable to block IkBa degradation (Fig. 4C, lanes 4
(lane 4), 1 (lane 5) or 5 mM (lane 6) AD, 1 (lane 7) or 5 mM (lane 8)
to 12). This experiment demonstrated that inhibition of DD, and 1 (lane 9) or 5 mM (lane 10) TD. Levels of IkBb and actin are
NF-kB DNA-binding activity correlated directly with inhi- shown (middle and bottom, respectively). (C) Analysis of IkB degrada-
tion in NIH 3T3 cells. Cells were pretreated 1 hr with 0.1 mM PDTCbition of IkBa degradation by the different compounds.
(lane 3), 17 hr with 10 to 100 mM desferal (lanes 4 to 6), 1 to 100 mM
PIH (lanes 7 to 9), and 1 to 100 mM SIH (lanes 10 to 12). Levels ofInhibition of IkBa phosphorylation
IkBb and actin are shown (middle and bottom, respectively).
Phosphorylation of IkBa on serine 32 and/or serine
36 is a critical step in targeting IkBa for subsequent
ubiquitination and degradation by a 26S proteasome- various antioxidant compounds on IkBa phosphorylation,
we next examined the formation of the inducer-depen-mediated mechanism (Traenckner et al., 1995; Brown et
al., 1995; Sun et al., 1996). To examine the impact of the dent, hyperphosphorylated form of IkBa following a brief
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FIG. 5. Analysis of IkBa phosphorylation in the presence and absence of antioxidants. Jurkat cells were untreated or pretreated with antioxidants
for 1 or 17 hr and calpain inhibitor I for 30 min before stimulation with 10 ng/ml TNF-a, for either 1 or 5 min. Cell extracts were prepared, and
equal amounts of protein (30 mg) were separated by SDS–PAGE, transferred to nitrocellulose, and visualized with IkBa monoclonal antibody. (A)
Cells were pretreated 1 hr with 50 mM NAC (lanes 4 and 5), 0.1 mM PDTC (lanes 6 and 7), and 1 (lanes 8 and 9) and 5 mM TD (lanes 10 and 11).
(B) Cells were pretreated 17 hr with 0.1 (lanes 4 and 5) or 1 mM desferal (lanes 6 and 7), 10 (lanes 13 and 14) or 100 mM PIH (lanes 15 and 16),
and 10 (lanes 17 and 18) or 100 mM SIH (lanes 19 and 20).
exposure of cells to TNF-a treatment. Jurkat cells were a number of reporter gene constructs, including the HIV
incubated with different antioxidants for 1 hr and with LTR CAT gene. As inducer, the combination of TNF-a and
calpain inhibitor I for 30 min to prevent the proteolytic viral Tat protein was used, since together these inducers
degradation of IkBa, thus permitting the accumulation of provide a synergistic activation of HIV LTR-driven gene
phosphorylated IkBa. Cells were then induced with TNF- activity (9). Jurkat cells were transfected with the Tat-
a (10 ng/ml), and at 1 and 5 min after addition of TNF- expressing plasmid pSVexTat together with HIV LTR CAT
a, whole-cell extracts were prepared and analyzed either reporter plasmid or different HIV LTR deletion constructs.
by 5–13% gradient or 15% SDS–PAGE. Hyperphosphory- Stimulation of HIV LTR-dependent gene activity by TNF-
lated IkBa was visualized by immunoblotting using the a alone (Fig. 6A, lane 5) resulted in a 1.5-fold increase
monoclonal IkBa antibody (Fig. 5). As rapidly as 1 min in reporter gene activity while Tat protein alone (Fig. 6A,
after TNF-a treatment, a slower migrating form of phos- lane 9) stimulated gene expression about 60-fold. Addi-
phorylated IkBa was detected (Fig. 5A, lane 2); this form tion of both activators (Fig. 6A, lane 13) produced a syner-
accumulated during the next 5 min and represented gistic 400-fold increase in gene activity compared to
about 40% of the total IkBa pool at 5 min after TNF-a basal level. When cells were treated with NAC, PDTC, or
induction (Fig. 5A, lane 3). Pretreatment of cells with NAC Trimidox prior to stimulation by TNF-a, strikingly different
(50 mM), PDTC (0.1 mM), and Trimidox (5 mM) signifi- results were obtained. Cells treated with 50 mM NAC
cantly inhibited the accumulation of phosphorylated IkBa (Fig. 6A, lanes 2, 6, 10, and 14) or with 1 mM TD (Fig.
(Fig. 5A, lanes 4–11). In a separate experiment, the iron 6A, lanes 4, 8, 12 and 16) showed a significant decrease
chelators desferal at concentrations of 0.1 and 1.0 mM in Tat/TNF-a induced HIV LTR activity (approximately 3-
(Fig. 5B, lanes 4–7), PIH at concentrations of 10 and 100 fold and 13-fold inhibition, respectively). Trimidox was
mM (Fig. 5B, lanes 13–16), and SIH at concentrations of inhibitory to both TNF-a-induced and Tat-induced HIV
10 to 100 mM (Fig. 5B, lanes 17–20) had no inhibitory LTR activity, whereas NAC had little or no effect on Tat-
effect on TNF-a-induced phosphorylation of IkBa. There- mediated gene activity. In contrast, cells pretreated with
fore, the antioxidants NAC and PDTC, as well as the 0.1 mM PDTC (Fig. 6A, lanes 3, 7, 11, and 15) displayed
ribonucleotide reductase inhibitor TD, exert their inhibi- high levels of gene activity regardless of the presence
tory effect on TNF-a-induced NF-kB activity by inhibiting or absence of TNF and/or Tat. The iron chelator desferal
IkBa phosphorylation, a prerequisite step for degrada- (Fig. 6B, lanes 2, 6, 10, and 14) showed very little inhibi-
tion. In contrast, the iron chelator desferal had no effect tory effect on LTR-mediated gene activation (approxi-
on the TNF-a-induced phosphorylation. mately 10% inhibition in the presence of TNF-a and Tat),
while PIH (Fig. 6B, lanes 3, 6, 11, and 15) and SIH (Fig.
Selective inhibition of HIV LTR-mediated gene 6B, lanes 4, 8, 12, and 16) demonstrated approximately
activation by antioxidants 30% inhibition. These experiments demonstrated that
NAC and Trimidox efficiently inhibited HIV-1 LTR-drivenWe next investigated the inhibitory effects of the differ-
ent compounds on NF-kB-dependent gene activity using gene expression, whereas PDTC was not effective, even
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FIG. 6. Effect of antioxidants on HIV LTR-mediated gene expression. Jurkat cells were transfected with 5 mg CAT reporter plasmid with either
HIV LTR (A and B) or HIV LTR (0109/79) (C), which is deleted for the NF-kB sites, with or without HIV-1 Tat-expressing plasmid, pSVexTat (2 mg).
Cells were induced by 10 ng/ml TNF-a in the presence of various antioxidants at indicated concentrations. The level of LTR-driven transcription
was determined by CAT assay on the total cell extract. Results shown are representative of a typical experiment. h Untreated cells, ¿ NAC 50
mM, … PDTC 0.1 mM, j TD 1 mM, ii/home2/milesgrsym/8point/gs20,l(3,0) desferal 100 mM, ° PIH 100 mM, ‰ SIH 100 mM. Percentage conversion
for control (column 1) in A and B is 3.3% and percentage conversion for control (column 1) in C is 1.0%.
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FIG. 6—Continued
though this antioxidant was capable of blocking IkBa and 15) showed either no effect or a slight enhancement
in reporter gene activity, regardless of the presence orphosphorylation. Moreover, iron chelators PIH and SIH
slightly inhibited LTR-driven gene expression, apparently absence of the two activators. These experiments con-
firmed the absolute requirement of the NF-kB-bindingby an NF-kB-independent mechanism.
sites for the Tat–TNF-a synergistic activation of the HIV
Antioxidant inhibition requires the NF-kB sites LTR and also demonstrated that NAC and TD mediated
their effects by interfering with NF-kB activation.Since Tat–TNF-a synergistic activation of HIV LTR re-
quires intact NF-kB-binding sites (Beauparlant et al.,
Antioxidants showed distinct effects on NF-kB-
1996b), we examined whether antioxidant inhibition
dependent activity induced by TNF-a
would be abolished when the NF-kB-binding sites were
deleted from the HIV LTR (0109/79) reporter plasmid. As In order to correlate the inhibitory effect of antioxidants
on NF-kB DNA-binding with gene activity, NF-kB-depen-shown in Fig. 6C, the basal activity of the (0109/79) re-
porter plasmid was lower compared to the WT HIV LTR; dent reporter gene activity was evaluated using two con-
structs: pHIVenh-CAT plasmid, composed of the two NF-also, TNF-a stimulation of 0109/79 activity was abro-
gated (Fig. 6C, lane 5). The fold increase by Tat protein kB-binding sites of the HIV enhancer, linked to an SV40
promoter (Hiscott et al., 1989), and the 5*kB(3) CAT plas-(53-fold) was comparable to that seen with the WT HIV
LTR construct; however, synergistic activation by Tat and mid with three tandem copies of the HIV enhancer linked
to the SV40 promoter. In both cases, observed reporterTNF-a was abolished. In cells treated with 50 mM NAC,
reporter gene activity was not significantly inhibited (Fig. gene activity will be solely attributed to NF-kB-mediated
transcription. Analysis of these two plasmids demon-6C, lanes 2, 6, 10, and 14) (about 20% inhibition in the
presence of TNF-a and Tat). Cells treated with 1 mM TD strated 6.7-fold (Fig. 7A, lane 5) and 2.4-fold (Fig. 7B,
lane 5) increase in reporter gene activity upon TNF-a(Fig. 6C, lanes 4, 8, 12, and 16) also showed some inhibi-
tion of reporter activity in the presence of activators (1.2- induction, with the 5*kB(3) CAT construct having a higher
basal activity than pHIVenh-CAT (Fig. 7B, lane 1). Pre-fold inhibition), although the inhibition was significantly
less than with the WT LTR construct (13-fold inhibition). treatment of cells with 50 mM NAC (Figs. 7A and 7B,
lane 6) and 1 mM TD (Figs. 7A and 7B, lane 8) loweredCells treated with 0.1 mM PDTC (Fig. 6C, lanes 3, 7, 11,
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FIG. 7. Antioxidants inhibit NF-kB-dependent transcription. Jurkat cells were transfected with 5 mg (A) pHIVenh-CAT or (B) 5*kB(3) CAT, which
depend on NF-kB binding for gene activation (described under Methods and Materials) with or without HIV-1 Tat plasmid (2 mg). Cells were induced
by 10 ng/ml TNF-a in the presence of various antioxidants at indicated concentrations. The level of LTR-driven transcription was determined by
CAT assay on the total cell extract. h Untreated cells, ¿ NAC 50 mM, … PDTC 0.1 mM, j TD 1 mM. Percentages of conversion for control (column
1) in (A) pHIVenh-CAT and (B) 5*kB(3) CAT are 3.1 and 7.1%, respectively.
the TNF-a-induced activity to basal level. Interestingly, We found in Jurkat and NIH 3T3 cell models that NAC,
PDTC, and TD all inhibited NF-kB DNA-binding activity,pretreatment with 0.1 mM PDTC (Figs. 7A and 7B, lane
due to an inhibition of IkBa degradation. Among the three7) did not show any inhibitory effect. In fact, the reporter
ribonucleotide reductase inhibitors, TD was the most po-activity increased in the presence of PDTC when cells
tent NF-kB inhibitor and was therefore chosen for subse-were stimulated by TNF-a. Also, cotransfection of HIV
quent experiments. Iron chelators including desferal,Tat protein slightly upregulated basal NF-kB-dependent
PIH, and SIH, on the other hand, showed no inhibitiontranscription (1.7-fold) with the 5*kB(3) construct studies
of NF-kB DNA-binding activity or IkBa degradation within(Fig. 7B, lane 9). In conclusion, these experiments dem-
the concentration range tested. Hyperphosphorylation ofonstrate an inhibitory role of NAC and TD on NF-kB-
IkBa, an obligatory step required for its degradation, wasdependent gene expression.
inhibited by the addition of NAC, PDTC, and TD but not
desferal, PIH, or SIH. In all cases, the degree of inhibitionDISCUSSION
by different compounds on DNA binding, IkBa degrada-
Previous studies have demonstrated inhibition of NF- tion, and IkBa phosphorylation directly correlated with
kB activity by antioxidants and iron chelators, suggesting each other. Degradation of IkBb was excluded from the
a role of oxidative stress in the pathway of NF-kB activa- contribution to NF-kB activation by TNF-a, since a stable
tion. In the present studies, we examined the steps in level of IkBb protein was observed after TNF-a induction.
NF-kB activation that may be influenced by the oxidative The effects of antioxidant compounds on NF-kB gene
state of the cell by examining the effects of several novel activation were examined as well using reporter gene
or established compounds on TNF-a-induced NF-kB ac- assay. In Jurkat cells, NAC and TD showed complete
tivation. Also, we investigated the effects of these com- inhibition of HIV LTR-mediated transcription induced by
pounds on the synergistic activation of the HIV-1 LTR TNF-a. Surprisingly, despite the inhibitory effect of PDTC
brought about by Tat protein and TNF-a. Among the com- on NF-kB DNA-binding activity and IkBa degradation,
pounds used in our experiments were antioxidants (NAC, the addition of PDTC did not repress NF-kB-dependent
PDTC), ribonucleotide reductase inhibitors (AD, DD, TD), gene activation. In most cases, PDTC even enhanced
gene expression. Similar results were observed whenand iron chelators (desferal, PIH, SIH).
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the effects of these compounds were examined in the lated antioxidant compounds prevents NF-kB activation
at the step of IkBa phosphorylation, thus confirming thecontext of HIV-1 LTR. Upon addition of NAC and TD,
significant inhibition of LTR activity was observed in the involvement of ROI in NF-kB activation. Chen et al. have
recently identified a large 700-kDa multisubunit kinasepresence of synergistic activators HIV-1 Tat protein and
TNF-a. Our results indicate that inhibition of the NF-kB that phosphorylates IkBa at S32 and S36 in vitro (Chen
et al., 1996). Strikingly, this kinase requires prior ubiquiti-component of Tat–TNF-a synergistic activation of HIV-1
LTR with NAC or TD significantly repressed the level of nation to activate kinase activity. Whether this kinase
activity per se or the prerequisite ubiquitination relies ongene transcription. Moreover, PIH and SIH showed some
inhibition of HIV LTR activation while desferal did not. an oxidative stress signal for activation remains un-
known. Alternately, inducible IkBa phosphorylation mayThe inhibitory effects of SIH on HIV LTR activation pre-
sumably occur by an NF-kB-independent mechanism, be mediated by an as yet uncharacterized kinase whose
activation depends on oxidative stress signal.since there is no apparent effect of these compounds on
TNF-a-induced NF-kB activity. Conclusively, ribonucleo- The interplay between different ROI species within the
cell is both complicated and tightly controlled. Cellulartide reductase inhibitor TD, at concentration 50 times
lower than the working concentration of NAC, inhibits mechanisms have evolved to counteract the detrimental
action of different ROI species such as superoxide radi-NF-kB activation. It also effectively inhibits HIV LTR gene
expression, suggesting that it may be a suitable candi- cals (O•02 ), hydrogen peroxide (H2O2), and hydroxyl radical
(OH•). In mammalian cells, major antioxidant enzymesdate for anti-HIV pharmaceutical therapy.
The lack of an inhibitory effect on LTR gene activity by include superoxide dismutase (SOD), glutathione peroxi-
dase (GSHPx), and catalase. SOD converts O•02 to H2O2 ,PDTC is contradictory to previous reports demonstrating
that PDTC pretreatment inhibited the activity of HIV LTR which is further converted to OH• through the Fenton
reaction in the presence of ferrous iron. GSHPx detoxifies(Schreck et al., 1992a,b), although the inducers used pre-
viously were HTLV-1 Tax protein and PMA/PHA. Differ- H2O2 by reducing H2O2 to H2O while oxidizing the cosub-
strate GSH. Previous reports demonstrated increasedences in the inducers and/or the signaling pathway acti-
vated by Tax or PMA/PHA may contribute to differential TNF-a-induced NF-kB activation by overexpression of
MnSOD (Schreck et al., 1992b) or Cu/ZnSOD (Schmidt etsensitivity to PDTC. Meanwhile, a recent report (Nobel
et al., 1995) questioned the role of PDTC as an antioxi- al., 1995) and decreased NF-kB activity by overex-
pression of catalase (Schmidt et al., 1995) or GSHPxdant in the cell. Addition of PDTC helps transportation of
extracellular copper from media into cells and this leads (Kretz-Remy et al., 1996). Together with the observation
that NF-kB activation can be prevented by metal-chelat-to a subsequent increase in intracellular oxidized gluta-
thione (GSSG). Given that the correlation between an ing agents, which abrogate the iron-dependent Fenton
reaction, and by radical-trapping thiol agents, whichincrease of GSSG and inhibition of NF-kB activation by
PDTC has been observed previously (Galter et al., 1994), scavenge hydroxyl radicals, it appears that the form of
ROI which mediates NF-kB activation is the hydroxyl radi-it is possible that this unique effect of PDTC is responsi-
ble for its initial inhibitory action on NF-kB. Eventual de- cal (Sappey et al., 1995; Schreck et al., 1992b). A sche-
matic diagram of events leading to TNF-a-mediated acti-composition of PDTC inside the cell is presumed to facili-
tate the intracellular release of chelated copper and vation of HIV-1 LTR by NF-kB induction is presented in
Fig. 8. Also, the potential point in the pathway that maythereby enhance the potential for oxidative damage.
Hence, it is possible that both initial inhibition and subse- be inhibited by the different compounds is indicated.
Use of compounds which suppress TNF-a-inducedquent activation of NF-kB activity are elicited by PDTC,
depending on the duration of treatment. If this is the NF-kB activity, especially antioxidants examined in this
study, may be a logical physiological approach to thecase, it may offer some explanation for our experimental
results, since we only observed consistent inhibitory ef- treatment of HIV-1-infected patients (Baruchel et al.,
1992; Muller, 1992). First, TNF-a levels are elevated (Lah-fect of PDTC on NF-kB activity in experiments which
require short-duration exposure to the compounds (e.g., devirta et al., 1988) and GSH levels are depleted (Buhl
et al., 1990) in the serum of patients with AIDS and these3 hr in nuclear extract for EMSA, 2 hr in whole-cell extract
for immunoblot). On the other hand, when cells were alterations lead to the generation of ROI inside the cell.
Second, HIV-1 Tat protein potentiates TNF-a-induced NF-exposed to PDTC for long duration (approximately 20 hr
as in LTR CAT activity analysis), we did not observe an kB activity by altering the cellular redox state toward a
more prooxidative condition, which favors IkBa degrada-inhibitory effect on gene expression. Whether duration
of PDTC treatment is responsible for the discrepencies tion (Westendorp et al., 1995). Also, HIV-1 gp120 ampli-
fies TNF-a-induced NF-kB activation by increasing for-reflected from our data remains to be determined.
Formation of ROI is a crucial component of NF-kB mation of ROI (Shatrov et al., 1996). Third, Tat protein
and TNF-a synergistically activate HIV-1 LTR-driven geneactivation. Despite extensive studies on the mechanism
of NF-kB activation, identification of the exact step in transcription, and this process requires the presence of
NF-kB activity (Beauparlant et al., 1996b). Fourth, duringthe pathway which requires ROI remains unclear. Our
studies demonstrate that the addition of various unre- long-term, low-dose oxidative stress of cells, the HIV-1
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FIG. 8. Schematic diagram depicting the events leading to HIV-1 LTR activation by NF-kB induced by TNF-a and the involvement of ROI in NF-
kB-activation pathway.
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